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p21
WAF1/CIP1 is a universal cyclin-dependent kinase inhibitor. To investigate the role of p21
WAF1/CIP1 in proliferation of human
liver cancer cells, we examined the expression of p53, p21
WAF1/CIP1, cdk2 and cdk4 expression in two human liver cancer cell
lines (HepG2 and PLC/PRF/5 cells). The effects of p21
WAF1/CIP1 on [
3H]thymidine incorporation and cdks were also examined
in these cells. HepG2 cells expressed all these proteins with lower level of cdk4. PLC/PRF/5 cells expressed the other proteins
except p21
WAF1/CIP1. Transfection of p21
WAF1/CIP1 gene inhibited [
3H]thymidine incorporation of both cells with different
extent. Although the transfection of p21
WAF1/CIP1 did not affect cdk2 and cdk4 expression, it did reduce cdk2 kinase activity
by 20%. These results suggest that: (a) p21
WAF1/CIP1 involved in DNA synthesis of human liver cancer cells; (b) p21
WAF1/CIP1
could be a target gene for the treatment of human hepatocellular carcinoma.
British Journal of Cancer (2002) 86, 625–629. DOI: 10.1038/sj/bjc/6600099 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: p21
WAF1/CIP1;[
3H]thymidine incorporation; liver cancer
The cyclins and the cyclin-dependent kinases (cdks) are important
proteins regulating the checkpoints of cell cycle progression (Hunter
and Pines, 1994). In normal cells, checkpoints in the cell cycle play
an important role of guiding normal cell cycle while in cancer cells,
disruption of the checkpoints is responsible to abnormal growth of
cancer cells. Positive and negative regulatory mechanisms control
the regulation of the checkpoints in cell cycle. A cyclin-dependent
kinase inhibitor (cdki) mediates one of the negative regulations of
checkpoints (Sherr and Roberts, 1995). Recently, the p21
WAF1/CIP1
gene was cloned and mapped to the chromosome 6p21.2 region
(el-Deiry et al, 1993; Noda et al, 1994). p21
WAF1/CIP1 is considered
a universal cyclin-dependent kinase inhibitor. It inhibits several
cyclin-cdks complex as well as DNA synthesis by inactivating prolif-
eration cell nuclear antigen, a subunit of DNA polymerase d (Xiong
et al, 1993). In addition, p21
WAF1/CIP1 involves in induction of cell
differentiation (Skapek et al, 1995) and inhibition of tumour cell
proliferation (el-Deiry et al, 1994).
Mutation of p21
WAF1/CIP1 is rare in different types of human
malignancy, therefore, it is suggested that p21
WAF1/CIP1 exerts its
role in tumorigenesis mainly on expression level. It seems to be
true in human hepatocellular carcinoma (HCC). Several groups
studying expression of p21
WAF1/CIP1 in human hepatocellular carci-
noma have documented that there were reduced p21
WAF1/CIP1
mRNA and protein levels in human HCC (Hui et al, 1997; Naka
et al, 1998; Qin et al, 1998; Shi et al, 2000). These studies suggested
that disruption of p21
WAF1/CIP1 and cell cyclin-cdks complexes may
contribute to malignant progression of HCC. However, the direct
role of p21
WAF1/CIP1 in human HCC cells has not been explored.
In this study, we employ an expression vector of p21
WAF1/CIP1 to
examine the direct effect of p21
WAF1/CIP1 on human liver cancer
cells.
MATERIALS AND METHODS
Material
Minimum Eagle’s medium (MEM), sodium bicarbonate, sodium
pyruvate, penicillin-streptomycin, Trypsin-EDTA and Lipofectin-
AMINE were purchased from GIBCO/BRL (Life Technologies,
Burlington ON, Canada). Dr Alan McLachlan (Research Institute
of Scripps Clinic at La Jolla, CA, USA) kindly provided PLC/
PRF/5 human HCC cells. HepG2 cells were purchased from ATCC
(Rockville, MD, USA). Cool calf 1 and the other chemicals were
purchased from Sigma Co. (St. Louis, MO, USA). The mammalian
expression vector pCEP was purchased from Invitrogen (Carlsbad,
CA, USA). p21
WAF1/CIP1 and p53 antibodies were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). cdk2 and
cdk4 antibodies, rabbit anti-mouse IgG and protein A/agarose were
purchased from Transduction Laboratories (Lexington, KY, USA).
Cell culture
Two human liver cancer cell lines were employed because they
represent different states of differentiation. HepG2 is a well-differ-
entiated cell line and derived from human hepatoblastoma. PLC/
PRF/5 is a poorly differentiated cell line and derived from HCC
of a patient with HBV. HepG2 and PLC/PRF/5 cells were grown
in MEM containing 5% Cool Calf 1 (Sigma Co. St. Louis, MO,
USA) supplemented with 10 mmol L
71 L-glutamine, 1 mmol L
71
sodium pyruvate, 100 IU ml
71 penicillin and 100 mgm l
71 strep-
tomycin (GIBCO–BRL, Burlington, ON, Canada) in Falcon
75 cm ﬂasks. Cultures were maintained at 378C in a humidiﬁed
atmosphere of 95% O2 and 5% CO2.
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www.bjcancer.comRNA extraction and Northern blot analyses
Total RNA of HepG2 and PLC/PRF/5 cells was extracted by a
Lithium chloride/Urea method (Gong et al, 1995) and the polyA-
RNA was isolated by employing oligo-dT cellular column (Aviv
and Leder, 1972). Northern blot analysis was performed using
a-
32P-dCTP-labelled full-length human p21
WAF1/CIP1 cDNA and
b-actin probes as previously described (Gong et al, 1995). Brieﬂy,
6 mg of polyA- RNA was separated through 1% agarose gel, trans-
ferred onto GT-zeta nylon membrane (Bio-Rad, Burlington, ON,
Canada), hybridized overnight with the probes at 428C and washed
as per the manufacturer’s instructions.
Transient transfection
1610
5 cells were seeded in 6-well plate one day before the transfec-
tion. Mock (water), pCEP or pCEP-WAF1 was mixed with
LipofectinAMINE and the mixtures were then incubated with cells
for 24 h. After 24 h, cells were washed and incubated with culture
media without antibiotics for a further 24 h followed by culturing in
completed media for 36 h to allow expression of p21
WAF1/CIP1 gene.
Cell proliferation assay
For cell doubling time, both cell lines were plated at 1610
5 cells in
6-well plates, cell numbers were counted at days 2 and 6 after seed-
ing. Cell doubling time was calculated according to the formula
(doubling time=t6log 2/log Nt/Ni, where t=time between the
count, Nt=cell number at day 6 and Ni=cell number at day 2)
as described previously (Gong et al, 1991). For
3H-thymidine
incorporation assays, cells transfected as delineated above were
labelled with 10 mCi of
3H-thymidine (speciﬁc activity
45 Ci mmol
71, Amersham, Oakville, ON, USA) for 2 h, ﬁxed in
10% trichloroacetic acid and lysed in 400 ml of 0.2M sodium
hydroxide. One hundred ml of the cell lysate was employed to
measure [
3H]thymidine incorporation with a LKB liquid scintilla-
tion counter (Wallac, Turku, Finland) and 10 ml of the cell lysate
was used to measure protein content by the Lowry technique.
The Western blot analyses
Cells non-transfected or transfected with mock, pCEP vector, and
pCEP-WAF1 as delineated above were lysed in 100 mlo f2 6 load-
ing buffer (125 mmol L
71 Tris-HCl, pH 6.8, 4% SDS, 20%
glycerol, 0.1% bromophenol blue and 2.5% b-mercaptoethanol).
Twenty mg of cell lysate from each sample was separated in a
15% polyacrylamide/SDS gel, transferred onto Nitroplus-2000
membranes (Micron Separations Inc. Westborough, MA, USA)
and incubated with antibodies against p53, p21
WAF1/CIP1, cdk2
and cdk4 respectively. Immunoreactive bands were visualized by
using the ECL (enhanced chemiluminescence) detection method
(Amersham, Arlington Heights, IL, USA) (Gong et al, 1995).
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Figure 1 Expression of p53, p21
WAF1/CIP1, cdk2 and cdk4 in HepG2 and PLC/PRF/5 cell lines. (A) Shows Western blot analysis of p53, p21
WAF1/CIP1, cdk2
and cdk4 in HepG2 and PLC/PRF/5 cells. Twenty mg of each cell lysate was resolved in 15% polyacrylamide/SDS gel and incubated with antibodies against
p53, p21
WAF1/CIP1, cdk2 and cdk4 respectively. (B) Shows histogram of densitometry of Western blot analyses of p53, p21
WAF1/CIP1, cdk2 and cdk4 from
four individual experiments (mean+s.e.). (C) Shows Northern blot analysis of p21
WAF1/CIP1 mRNA abundance in HepG2 and PLC/PRF/5 cells. Six mgo f
polyA- RNA from each cell line was separated in 1% agarose and hybridized with the full length human p21
WAF1/CIP1 cDNA and b-actin cDNA probes
respectively.
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Immunokinase assay was performed following a protocol from
Transduction Laboratories (Lexington, KY, USA). Brieﬂy, cells with
no transfection and transfection of mock, pCEP vector, and pCEP-
WAF1 as described above were lysed in 1 ml cold lysis buffer
(10 mmol L
71 Tris-HCl pH 7.4, 1.0% Triton X-100, 0.5% Nonidet
P-40, 150 mmol L
71 NaCl, 20 mmol L
71 Sodium ﬂuoride,
0.2 mmol L
71 sodium ortho-vanadate, 1.0 mmol L
71 EDTA,
0.2 mmol L
71 PMSF) for 30 min at 48C. One mg of the total cell
lysate was employed to incubate with 5 mg of mouse monoclonal
antibodies against cdk2 and then with the same amount of rabbit
anti-mouse IgG. After centrifugation, the immune complexes were
further incubated with 10 ml of the 50% protein A:agarose suspen-
sion. The immunocomplexes were suspended in 40 ml of kinase
buffer (10 mmol L
71 Tris-HCl pH 7.4, 150 mmol L
71 NaCl,
10 mmol L
71 MgCl2, 0.5 mmol L
71 DTT) with 25 mM ATP,
2.5 mCi [
32P-g]-ATP and 1 mg ml
71 histone 1 and then incubated
at 378C for 15 min. The reactions were then electrophoresed on
15% SDS–PAGE and kinase activities were indicated by the band
of histone 1.
RESULTS
We employed two human liver cancer cell lines to investigate the
direct effect of p21
WAF1/CIP1 on these cells. The two human liver
cancer cell lines – HepG2 and PLC/PRF/5 exhibited very differ-
ent expression pattern of p53, p21
WAF1/CIP1, cdk2 and cdk4. By
Western blot analyses, p53, p21
WAF1/CIP1, cdk2 and cdk4 can
be detected in HepG2 cells while p53, cdk2 and cdk4 were
observed in PLC/PRF/5 cells (Figure 1A). Moreover, the abun-
dance of p53 protein in HepG2 cells was higher than that of
PLC/PRF/5 cells. Furthermore, cdk4 protein level was higher in
PLC/PRF/5 cells than in HepG2 cells (Figure 1B). Although
p21
WAF1/CIP1 protein was not observed in PLC/PRF/5 cells, its
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Figure 2 The upper panel shows Western blot analyses of transfected
p21
WAF1/CIP1 protein in HepG2 and PLC/PRF/5 cells. Both cell lines were
transfected with mock (with water), pCEP (2 mg) and pCEP-WAF1
(2 mg). Twenty mg of each cell lysate was resolved in 15% SDS–PAGE
and transferred onto Nitroplus-2000 membrane. The membranes were
then incubated with antibody against p21
WAF1/CIP1. The lower panel shows
histogram of densitometry of Western blot analyses of transfected
p21
WAF1/CIP1 protein in both cell lines. The data represents mean+s.e.
(n=4).
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Figure 3 The effect of p21
WAF1/CIP1 on [
3H]thymidine incorporation in
HepG2 and PLC/PRF/5 cells. (A) Shows the effect of different concentra-
tions of pCEP and pCEP-WAF1 on [
3H]thymidine incorporation in HepG2
cells. The data represents mean+s.e. (n=8). (B) Shows the effect of differ-
ent concentrations of pCEP and pCEP-WAF1 on [
3H]thymidine incorpora-
tion in PLC/PRF/5 cells. The data represents mean+s.e. (n=8). **Indicates
P50.01. (C) Displays correlation between densities of p21
WAF1/CIP1 and
[
3H]thymidine uptake in PLC/PRF/5 cells. Cells were transfected with 0.1,
0.5, 0.75, 1 and 2 mg of p21
WAF1/CIP1 cDNA. The densities of p21
WAF1/
CIP1 protein and [
3H]thymidine uptake were plotted by StatView regression
program. There is a statistically signiﬁcant correlation between thymidine
uptake and density (P=0.0258).
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compared to that in HepG2 cells (Figure 1C). Furthermore,
the expression of p21
WAF1/CIP1 was related to longer cell doubling
time (HepG2 cells 44+4h vs PLC/PRF/5 cells 29+3h ,
P50.05). Under the same transfection condition, the p21 level
as the result of transfection in PLC/PRF/5 cells was four times
than that in the HepG2 cells. However, the total p21 levels in
PLC/PRF/5 cells after transfection was about twice of that in
the HepG2 cells (Figure 2).
The effects of p21
WAF1/CIP1 on cell proliferation of two human
liver cancer cells were shown in Figure 3. The p21
WAF1/CIP1 inhib-
ited cell proliferation of both HepG2 and PLC/PRF/5 cells with
different extent. Although lower than pCEP vector control, the
p21
WAF1/CIP1 did not signiﬁcantly inhibit HepG2 cell proliferation
(Figure 3A). However, the p21
WAF1/CIP1 inhibited PLC/PRF/5 cell
proliferation in a dose-dependent manner. Progressive increases
in the amount of transfected p21
WAF1/CIP1 cDNA resulted in a
progressive inhibition of PLC/PRF/5 cell proliferation until maxi-
mum inhibition was obtained at 2 mg of the p21
WAF1/CIP1 cDNA.
When compared to cell proliferation associated with transfection
of the pCEP vector alone, the differences were statistically signiﬁ-
cant (P50.01, Figure 3B). Moreover, inhibition of [
3H]thymidine
incorporation was correlated with the expression of p21
WAF1/CIP1
protein in PLC/PRF/5 cells (Figure 3C). To elucidate the mechan-
ism of p21
WAF1/CIP1 inhibition of cell proliferation, we examined
the p21
WAF1/CIP1 regulation of cdk2 and cdk4 in both PLC/PRF/5
and HepG2 cells. Our results showed that the p21
WAF1/CIP1 did
not alter either cdk2 or cdk4 proteins in these cells (Figure 4A).
The cdk2 kinase activity was further examined by immunokinase
assay. Although cdk2 kinase activity was higher in PLC/PRF/5 cells
than that in HepG2 cells, the p21
WAF1/CIP1 reduce cdk2 kinase
activity by 20% in both cells (Figure 4B).
DISCUSSION
p21
WAF1/CIP1 was identiﬁed as a potential mediator of p53 protein
and a co-immunoprecipitated protein of cyclin D1 (Xiong et al,
1992; el-Deiry et al, 1993). Extensive studies reveal that p21
WAF1/
CIP1 involves in the progression of cell cycle. It inhibits several
cyclin-cdk activities and also is a component of proliferating nucle-
ar antigen (PCNA) and DNA polymerase d complexe (Sherr and
Roberts, 1995). The p21
WAF1/CIP1 protein contains two functional
domains, which are mediated in the inhibition of cdk kinase and
binding of PCNA. The amino end of p21
WAF1/CIP1 contains an
inhibitory domain of cdk, which inhibits cyclin D and E associated
cdks activities. The carboxyl end of p21
WAF1/CIP1 mediates the
PCNA-binding and activity of DNA polymerase d (Chen et al,
1995; Luo et al, 1995; Nakanishi et al, 1995; Warbrick et al,
1995). Our results showed that p21
WAF1/CIP1 inhibited [
3H]thymi-
dine incorporation and reduced cdk2 kinase activity in human liver
cancer cells but did not affect expression of cdk2 and cdk4. The
ﬁndings suggest that the transfected p21
WAF1/CIP1 likely has no
apparent effect on the expression of cdks but may block the ability
of PCNA to activate DNA polymerase d and the cdk kinase activity
in human liver cancer cells. The distinguished action of p21
WAF1/
CIP1 was demonstrated in a SV40-based DNA replication system.
In this in vitro DNA replication system, p21
WAF1/CIP1 was able to
block PCNA-activated DNA polymerase d activity without the
participation of cyclin-bound cdks (Flores-Rozas et al, 1994; Waga
et al, 1994).
The role of p21
WAF1/CIP1 in tumorgenesis of human hepatocellu-
lar carcinoma (HCC) is not clear. However, reduction of p21
WAF1/
CIP1 mRNA and protein abundance was observed in human HCC
(Naka et al, 1998; Qin et al, 1998). Studies of p21
WAF1/CIP1 mRNA
abundance in human HCC from Chinese and Japanese groups
showed some controversies (Naka et al, 1998; Qin et al, 1998).
The difference could be due to the infection of different hepatitis
viruses as well as non-viral infection. One of the Japanese groups
showed that HCC developed from p53-altered and HCV infected
patients exhibited reduced p21
WAF1/CIP1 protein abundance while
there was little change of p21
WAF1/CIP1 protein level in those
patients with HBV infection or no viral infection (Shi et al,
2000). Their ﬁnding was supported by that HCV core protein
inhibited the promoter activity of p21
WAF1/CIP1 gene (Ray et al,
1998). But the reduction of p21
WAF1/CIP1 mRNA abundance in
HCC could be more complicated because of p53 gene status in
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Figure 4 Both HepG2 and PLC/PRF/5 cells were treated as indicated –
none – no transfection, mock – transfection with water, pCEP vector and
pCEP-WAF1. (A) Shows the effect of p21
WAF1/CIP1 on cdk2 and cdk4 pro-
tein abundance in these cells. Twenty mg of each cell lysate was used for
Western blot analyses and the experiment was repeated on three occa-
sions. (B) Shows the effect of cdk2 kinase activity in these cells. The cell
lysates (1 mg of each) were immunoprecipitated with anti-CDK2 antibody
and the immunoprecipitates were incubated with a reaction solution for in
vitro phosphorylation of histone H1 as described in Materials and Methods.
Samples were then electrophoresis and phosphorylated histone 1 was vi-
sualized by autoradiography of the slab gels. (C) Displays the histogram
of cdk2 kinase activity. The data was generated from four separated experi-
ments and represented as mean+s.e. The no transfection was arbitrarily
set as 1.
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cells, which were derived from an African man with HBV infection
and carry HBV genome (Aden et al, 1979; Koch et al, 1984).
However, we observed that there was no expression of p21
WAF1/
CIP1 protein and the induced expression of p21
WAF1/CIP1 protein
signiﬁcantly inhibited [
3H]thymidine incorporation in PLC/PRF/5
cells. Because there is a mutation of p53 gene in PLC/PRF/5 cells
(Hsu et al, 1993), the absence of p21
WAF1/CIP1 protein in PLC/
PRF/5 cells could be related to p53 gene rather than viral infection.
It is consistent with HepG2 cells because HepG2 cells carry wild
type p53 gene and no HBV genome (Hosono et al, 1991). In these
cells, the p21
WAF1/CIP1 level is higher than that in PLC/PRF/5 cells.
Therefore, the p21
WAF1/CIP1 mRNA abundance in human HCC
may be dependent on both the type of viral infection and p53 gene
status.
One of our ﬁndings was that the expression of p21
WAF1/CIP1
protein inhibited [
3H]thymidine incorporation in human liver
cancer cells no matter of whether there was viral infection or muta-
tion of p53 genes. The difference between HepG2 and PLC/PRF/5
cells was the degree of inhibition of [
3H]thymidine incorporation.
This can be due to the ratio of p21
WAF1/CIP1 and cdks because the
ratio of p21
WAF1/CI and cdks could determine whether the p53 deﬁ-
cient cancer cells proliferated or not (Zhang et al, 1994; Shima et
al, 1998). In our case, that PLC/PRF/5 cells expressed no
p21
WAF1/CIP1 but higher cdk4 level made it more susceptible to
the inhibitory effect of p21
WAF1/CIP1. HepG2 cells expressed
p21
WAF1/CIP1 and had lower cdk4 level, therefore, HepG2 cells were
less sensitive to the effect of p21
WAF1/CIP1.
In conclusion, our present study has shown that: (a) HepG2 and
PLC/PRF/5 have distinguished expression pattern of p53, p21
WAF1/
CIP1, and cdk4; (b) although both cells exhibited the same level of
cdk2, activity of cdk2 was higher in PLC/PRF/5 cells than in
HepG2 cells; (c) p21
WAF1/CIP1 inhibited [
3H]thymidine incorpora-
tion and cdk2 kinase activity in both HepG2 and PLC/PRF/5
cells, however, the most signiﬁcant inhibition was observed in
PLC/PRF/5 cells; (d) since p21
WAF1/CIP1 inhibited DNA synthesis
of human liver cancer cells, p21
WAF1/CIP1 could be a target gene
for the treatment of human HCC.
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